Restructuring and consolidation dominated small-cap news, with Nostrum Oil & Gas pushing back its bond tender deadline as a Kazakhstan asset sale reshapes creditor recoveries, while Oakley Capital and RTW Biotech both crystallised gains on portfolio exits to larger acquirers.
Elsewhere, a clutch of winding-down vehicles, Riverstone Energy and Digital 9 Infrastructure, returned cash to shareholders, and resource and biotech names delivered incremental but meaningful technical progress.
Oakley Capital's Fund VI takes majority stake in Graphwise
Oakley Capital Investments (LSE:OCI), said Oakley Capital Fund VI has agreed to acquire a majority stake in Graphwise (LSE:OCI), a semantic data technology firm the private equity investor positions as a key enabler of enterprise artificial intelligence. OCI's indirect contribution through the fund is expected to reach up to approximately £20 million, its share of the wider transaction.
Graphwise structures enterprise data into knowledge graphs, a database format that adds context and connections so large language models can retrieve facts reliably rather than simply process language, and counts more than 200 blue-chip customers, concentrated in regulated sectors such as financial services, life sciences and the public sector where auditability and governance matter most. The company formed in 2024 through the merger of Sofia-founded Ontotext and Vienna-based Semantic Web Company, and has delivered organic annual recurring revenue growth of more than 30%.
"AI is changing how every organisation operates, but it also makes trusted, well-governed data more important than ever. Graphwise has built an exceptional platform to solve that challenge and has already demonstrated impressive growth," said Peter Dubens, founder of Oakley Capital.
The deal fits a pattern of private equity chasing the infrastructure layer beneath AI hype rather than the applications themselves, betting that governed, auditable data will remain a bottleneck for enterprise AI adoption regardless of which language models win out. For Oakley, a relatively modest £20 million ticket buys exposure to a business already growing at scale in the highest-value verticals.
BioMarin to acquire Alesta from RTW Bio's portfolio
RTW Biotech Opportunities, the closed-end fund investing across public and private biotech, said BioMarin will acquire its portfolio company Alesta Therapeutics for up to $490 million. Alesta is developing ALE1, an oral small-molecule therapy for hypophosphatasia, a rare inherited disease that impairs bone and tooth mineralisation, with BioMarin paying $275 million upfront in cash and up to a further $215 million contingent on milestones.
Alesta will spin out its non-ALE1 assets into a new entity before close, with existing shareholders including RTW Bio retaining pro rata stakes. RTW Bio first backed Alesta's Series A round in December 2024 and invested again in September 2025, committing €2.4 million in total; its holding was valued at $3.8 million as at 31 July, representing 0.4% of the fund's net asset value. The upfront payment implies a 41% uplift to that carrying value, adding an estimated $1.6 million, or 0.2%, to NAV.
"BioMarin's decision to acquire the company at pre-Phase 2 data is a clear validation of our strategy of identifying and supporting differentiated science at the earliest stages of the private markets," said Rod Wong.
The sale is the sixth acquisition from RTW Bio's private portfolio, reinforcing a model of backing rare-disease assets early and exiting well before pivotal data reads out. That a large pharma buyer is willing to pay a premium ahead of Phase 2 results underscores confidence in the underlying science, but for RTW Bio the NAV impact is modest, the real value is validation of a repeatable sourcing strategy rather than this single transaction's economics.
Nanoco confirms full-year trading in line with expectations
Nanoco Group (LSE:NANO), the developer and manufacturer of cadmium-free quantum dots and other nanomaterials, said trading for the year to 31 July was in line with market expectations, with the shares slipping 1.62% to 2.612p on the update. Unaudited revenue came in at £11.3 million, matching forecasts, though stripping out licence agreement income leaves underlying revenue of just £1.5 million.
Underlying unaudited adjusted EBITDA reached £6.1 million and cash stood at £9.3 million at year end, both slightly ahead of expectations, following a cost-base reorganisation that has cut the monthly gross cash cost to £0.3 million-£0.4 million from £0.5 million a year earlier. The company said it remains on track to hit all first-year milestones under its three-year joint development agreement with its first Asian chemical customer, with volumes expected to more than double in the 2027 financial year from a small base.
Discussions continue with a second Asian chemical customer following a small programme extension in June, alongside engagement with other potential partners. The gap between headline revenue and the £1.5 million underlying figure highlights how reliant Nanoco remains on licensing income rather than commercial volumes, making the pace of the 2027 ramp with its lead Asian partner the key variable for whether the cost discipline translates into a self-sustaining business.
Nostrum extends bond tender deadline to 2 September
Nostrum Oil & Gas (LSE:NOG), the offeror in an ongoing tender offer for its bonds, has pushed the deadline back from 21 August to 5:00 p.m. New York time on 2 September. The shares fell 39.96% to 1.501p, though the extension itself is a procedural response to what the company calls a material change to the tender offer stemming from a recently agreed asset sale, giving bondholders more time to digest the implications before committing.
The material change centres on Nostrum's exit from Kazakhstan: the company agreed in August to sell its Zhaikmunai and POSITIV Invest assets to Altaris Holding for $304.6 million, proceeds earmarked to repay creditors after senior secured notes matured on 30 June without repayment. Bondholders who have already submitted valid tender instructions need not resubmit them, while those who have not yet participated, or who previously withdrew, can still do so under the procedures set out in the tender offer memorandum dated 24 July, with Nostrum Oil & Gas Finance B.V. named as the associated issuing entity.
Proceeds from the Kazakhstan sale are earmarked first for senior secured noteholders in full, with senior unsecured noteholders targeted to receive around $150 million initially, a waterfall that leaves junior creditors most exposed to however the sale terms shift recovery math.
The extension does not alter the underlying restructuring trajectory, but it signals that the economics bondholders were asked to evaluate in July have moved enough to warrant a fresh look. With senior secured claims prioritised and the company effectively winding down its core Kazakh operations, the deal marks the practical endpoint of Nostrum as an operating business, what remains is a question of how the recovery waterfall gets divided among the layers of creditors still owed money.
Cooks Coffee confirms sales growth in first quarter
Cooks Coffee Company (COOK), trading at 5.1p, posted double-digit systemwide sales growth in the UK and Ireland alongside continued expansion of its Esquires franchise network in the first quarter.
The growth spans both existing store performance and new site openings, suggesting the franchise model continues to find demand even as broader consumer spending remains under pressure across UK retail and hospitality.
Ultimate Products confirms FY26 revenue in line despite decline
Ultimate Products (ULTP), down 4.56% to 53.256p, reported full-year revenue of £144.9 million, down from £150.1 million, as growth in proprietary brands offset weaker clearance sales and subdued consumer demand.
The homeware group's ability to hold revenue broadly in line with expectations despite the top-line decline points to a business mix shifting toward higher-margin proprietary brands, even as the clearance channel that once supplemented volumes continues to soften.
Henry Boot's Origin JV lets 404,100 sq ft of new space
Henry Boot (BOOT), up 0.64% at 155.999p, said its HBD industrial and logistics joint venture with Feldberg Capital has now let or agreed terms on 66% of its 711,000 sq ft portfolio, with 404,100 sq ft of that space let during the period.
The letting progress signals steady demand for industrial and logistics space even as broader property markets remain patchy, giving the joint venture a clearer line of sight to full occupancy across its remaining portfolio.
Riverstone Energy books $0.4 million profit as wind-down proceeds
Riverstone Energy (RSE), down 1.02% at 580.0p, returned £30 million to shareholders via redemption and banked $50 million from the sale of Onyx Power during its managed wind-down, posting a $0.4 million profit for the period.
The modest profit figure is incidental to the main story: Riverstone continues to monetise its remaining energy assets methodically and return capital, with the Onyx Power proceeds marking another step toward an orderly close-out of the vehicle.
iFOREX slashes profit guidance on Yen shock
iFOREX Financial Trading Holdings (IFRX), trading at 185.0p, now expects full-year 2026 adjusted EBITDA of just $0.5 million to $2.5 million after a sharp Yen appreciation and subdued trading activity hit August income.
The scale of the downgrade is stark for a retail trading platform whose earnings are directly exposed to currency volatility and client activity levels, with the Yen move evidently catching the book on the wrong side and client trading volumes failing to offset the impact.
Oberon Investments raises £1.4 million with director backing
Oberon Investments Group, the AQSE-listed wealth manager, sold shares at 2.1p to bolster working capital, with staff and directors contributing around £300,000 of the total raise.
Director participation at more than a fifth of the raise signals internal confidence in the fundraise, though the need to shore up working capital via equity rather than internally generated cash points to ongoing pressure on the business's balance sheet.
Malibu Life raises $125 million in fully subscribed placing
Malibu Life Holdings (MLHL), at 14.4p, completed its previously announced share sale in full, with strong shareholder take-up in the open offer triggering clawback from placees.
The fully subscribed outcome, and the clawback dynamic in particular, indicates existing shareholders were keen to maintain their proportional stakes rather than see dilution absorbed by new placees, a reasonable signal of confidence in the register.
Digital 9 Infrastructure returns £30 million in first wind-down redemption
Digital 9 Infrastructure (DGI9), up 1.77% at 4.6p, completed its first compulsory shareholder redemption since starting a managed wind-down, with net asset value per share slipping to 8.6p at the half-year.
The gap between the 8.6p NAV and the 4.6p share price highlights the discount investors continue to demand for wind-down uncertainty and execution risk, even as the company delivers on the mechanics of returning capital as promised.
Empire Metals confirms Pitfield as world's largest titanium resource
Empire Metals (EEE), up 1.74% at 46.7p, said an upgraded resource estimate lifts Pitfield's contained TiO2 to 349 million tonnes, with the first Measured category classification underpinning a move toward mine planning.
The addition of a Measured category is the more significant development for project financing purposes than the tonnage upgrade itself, since lenders and offtake partners typically require higher-confidence resource classifications before committing to development capital.
Nuformix reports positive preclinical data for IPF drug candidate
Nuformix (NFX) surged 35.29% to 0.1894p after an inhaled pharmacokinetic study showed NXP002 achieves lung concentrations expected to be therapeutically relevant, strengthening the fibrosis drug's licensing case.
The data supports the company's efforts to attract a licensing partner for NXP002 in idiopathic pulmonary fibrosis, a disease area where inhaled delivery mechanisms carry meaningful commercial appeal if concentration and safety data continue to hold up through further studies.
Rockfire drilling adds high-grade zinc hits at Molaoi
Rockfire Resources (ROCK), up 4.76% at 0.11p, reported that hole HMO-020 returned multiple zinc, silver and germanium intersections as the company pushes to upgrade the resource classification at its Molaoi project.
The germanium credits are notable given the metal's rising strategic profile in semiconductor and solar applications, adding a critical-minerals angle to what would otherwise be a straightforward base-metals resource upgrade story.
Tekcapital's Vesari files twelfth US patent application
Tekcapital (TEK), down 4.1% at 3.74p, said portfolio company Vesari has extended its intellectual property portfolio into satellite optical communications, filing a twelfth non-provisional US patent application tied to its geothermal-powered AI compute platform.
The steady accumulation of patent filings underpins Tekcapital's strategy of building defensible IP positions across its portfolio companies ahead of any commercialisation or licensing discussions.
Gana Media appoints Lorenzo Caci as chief operating officer
Gana Media Group, the iGaming and digital media group, has promoted Lorenzo Caci to chief operating officer after he led its Mexican gaming business through the World Cup period, with a board seat to follow.
The promotion rewards execution during a high-visibility commercial window and signals continuity in leadership as the group looks to build on that momentum across other markets.
Scancell wins MHRA clearance for Phase 3 melanoma trial
Scancell Holdings (SCLP), up 1.68% at 9.66p, secured UK regulator clinical trial authorisation clearing the path for a 550-patient registrational study of its lead immunotherapy iSCIB1+, with first survival data due in the second half of 2028.
MHRA clearance for a registrational trial marks a significant de-risking milestone, moving Scancell's lead asset from early-stage development into a defined path toward potential approval, though the 2028 data timeline means the clinical and financing runway ahead remains lengthy.
